WAYNE, Pa. — September 30, 2025 — Leads & Copy — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) will host its 2025 R&D Day in Midtown, New York on Tuesday, October 14, 2025, at 8:00 AM ET. The event will focus on the company’s progress in addressing therapeutic gaps in immuno-inflammatory markets. Presentations will be given by Aclaris leadership, Zuzana Diamant, MD, PhD, FERS, and Michael C. Cameron, MD, FAAD.
The presentations will highlight Aclaris’ development of kinase and immune pathway inhibitor franchises. Topics will include Aclaris’ work in developing small and large molecule product candidates, perspectives on its innovative discovery technology platform, progress with its ITK inhibition franchise, updates on its TSLP franchise, and new updates on ongoing and future clinical programs.
A live question and answer session will follow the presentation. A live and archived webcast of the event will be accessible on the Events page of the company’s website and available for at least 30 days.
Dr. Zuzana Diamant is affiliated with the University Medical Center Groningen, Netherlands; KU Leuven, Belgium; and Thomayer Hospital, Charles University, Prague. Dr. Michael Cameron is an Assistant Clinical Professor at Mount Sinai in New York and has expertise in drug development and inflammatory skin diseases.
Aclaris Therapeutics is developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases.
Contact: Will Roberts, Senior Vice President, Corporate Communications and Investor Relations, (484) 329-2125, wroberts@aclaristx.com
Source: Aclaris Therapeutics, Inc.
